Mutant genes in familial Alzheimer's disease and transgenic models

被引:474
|
作者
Price, DL [1 ]
Sisodia, SS
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Div Neuropathol, Baltimore, MD 21205 USA
关键词
presenilins; amyloid precursor protein; metabolism; function; A beta deposition;
D O I
10.1146/annurev.neuro.21.1.479
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The most common cause of dementia occurring in mid-to late-life is Alzheimer's disease (AD). Some cases of AD, particularly those of early onset, are familial and inherited as autosomal dominant disorders linked to the presence of mutant genes that encode the amyloid precursor protein (APP) or (he presenilins (PS1 or PS2). These mutant gene products cause dysfunction/death of vulnerable populations of nerve cells important in memory, higher cognitive processes, and behavior. AD affects 7-10% of individuals >65 years of age and perhaps 40% of individuals >80 years of age. For the late-onset cases, the principal risk factors are age and apolipoprotein (apoE) allele type, with apoE4 allele being a susceptibility factor. In this review, we briefly discuss the clinical syndrome of AD and the neurobiology/neuropathology of the disease and then focus attention on mutant genes linked to autosomal dominant familial AD (FAD), the biology of the proteins encoded by these genes, and the recent exciting progress in investigations of genetically engineered animal models that express these mutant genes and develop some features of AD.
引用
收藏
页码:479 / 505
页数:27
相关论文
共 50 条
  • [41] Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease
    Cuello, A. Claudio
    Hall, Helene
    Do Carmo, Sonia
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [42] Apoptosis and Alzheimer's disease: contribution of cellular and transgenic models
    Hugon, J
    Esclaire, F
    Terro, F
    Yardin, C
    REVUE NEUROLOGIQUE, 2000, 156 (02) : 123 - 125
  • [43] Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models
    Wisniewski, Thomas
    Boutajangout, Allal
    BRAIN STRUCTURE & FUNCTION, 2010, 214 (2-3): : 201 - 218
  • [44] Single and multiple transgenic mice as models for Alzheimer's disease
    van Leuven, F
    PROGRESS IN NEUROBIOLOGY, 2000, 61 (03) : 305 - 312
  • [45] Retinal Changes in Transgenic Mouse Models of Alzheimer's Disease
    Guo, Li
    Ravindran, Nivedita
    Shamsher, Ehtesham
    Hill, Daniel
    Cordeiro, M. Francesca
    CURRENT ALZHEIMER RESEARCH, 2021, 18 (02) : 89 - 102
  • [46] Cytokeletal alterations in transgenic models of Alzheimer's disease.
    Brion, JP
    Boutajangout, A
    Authelet, M
    Leroy, K
    Blanchard, V
    Pradier, L
    Tremp, G
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S240 - S241
  • [47] Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models
    Thomas Wisniewski
    Allal Boutajangout
    Brain Structure and Function, 2010, 214 : 201 - 218
  • [48] Transgenic mouse models of Alzheimer's disease: phenotype and application
    Higgins, GA
    Jacobsen, H
    BEHAVIOURAL PHARMACOLOGY, 2003, 14 (5-6): : 419 - 438
  • [49] Brain Biomarkers in Familial Alzheimer's Disease Mouse Models
    Kuttner-Hirshler, Yafit
    Venkatasubramanian, Palamadai N.
    Apolinario, Joan
    Bonds, Jacqueline
    Wyrwicz, Alice M.
    Lazarov, Orly
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 60 (03) : 949 - 958
  • [50] Erratum to: Animal Models of Alzheimer’s Disease: Utilization of Transgenic Alzheimer’s Disease Models in Studies of Amyloid Beta Clearance
    Tarja Malm
    Johanna Magga
    Jari Koistinaho
    Current Translational Geriatrics and Experimental Gerontology Reports, 2012, 1 (2): : 53 - 58